Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

Eli Lilly has amassed a market value nearing a trillion dollars based on the assumption that demand for its new weight-loss ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Fullerton also made tirzepatide, which is intended to mimic weight-loss and diabetes drugs Zepbound and Mounjaro. The FDA ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

I’d been wanting to lose weight for a while and the traditional methods just weren’t working for me. Deprive myself of carbs for a week and I would drop a measly 2lb. Hire a personal trainer – the ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...